Skip to main content
. 2013 Nov 17;2013:268486. doi: 10.1155/2013/268486

Figure 15.

Figure 15

(a) The IFN-γ levels in plasma samples measured by ELISA in different dose C16 treated groups. a P < 0.05 versus normal rats, b P < 0.05 versus vehicle control rats, and c P < 0.05 versus 0.5 mg/per day C16 treated EAE rats at 2 weeks after immunization. f P < 0.05 versus vehicle control rats; g P < 0.05 versus 0.5 mg/per day C16 treated EAE rats at 8 weeks after immunization. (a) The IFN-γ levels in plasma samples measured by ELISA in C16 late treated group. a P < 0.05 versus normal rats; b P < 0.05 versus vehicle control rats; c P < 0.05 versus 0.5 mg/per day C16 treated EAE rats; d P < 0.05 versus 1 mg/per day C16 treated EAE rats at 8 weeks after immunization. (c) The TGF-β levels in plasma samples measured by ELISA in different dose C16 treated group. a P < 0.05 versus normal rats. (d) The TGF-β levels in plasma samples measured by ELISA in C16 late treated group.